Disulfide bond-based drug delivery systems targeting the tumor microenvironment have emerged as a promising approach to enhance cancer treatment. Traditional chemotherapy faces challenges such as toxicity, poor solubility, and limited therapeutic efficacy. Disulfide bonds, which are responsive to reducing environments, can target high glutathione (GSH) levels in tumors, enabling precise drug delivery. These bonds can be combined with pH-responsive nanocarriers and tumor-specific ligands to improve targeting and drug release. Disulfide bonds can connect drugs, polymers, and carriers, facilitating targeted delivery and controlled release. Recent studies have explored various drug delivery systems based on disulfide bonds, including polymeric nanoparticles, liposomes, mesoporous silica nanoparticles, and others. These systems leverage the unique properties of disulfide bonds, such as their responsiveness to GSH and ROS, to enhance drug targeting and reduce systemic toxicity. Disulfide bonds also enable the design of multifunctional nanocarriers that can deliver multiple drugs, enhance therapeutic effects, and improve patient outcomes. The application of disulfide bonds in drug delivery systems has shown significant potential in improving cancer treatment by enhancing drug targeting, reducing side effects, and improving therapeutic efficacy. However, challenges remain in translating these systems into clinical practice, including optimizing drug loading, improving stability, and ensuring safe and effective delivery. Overall, disulfide bond-based drug delivery systems represent a promising strategy for targeted cancer therapy, with ongoing research aimed at further improving their clinical applicability.Disulfide bond-based drug delivery systems targeting the tumor microenvironment have emerged as a promising approach to enhance cancer treatment. Traditional chemotherapy faces challenges such as toxicity, poor solubility, and limited therapeutic efficacy. Disulfide bonds, which are responsive to reducing environments, can target high glutathione (GSH) levels in tumors, enabling precise drug delivery. These bonds can be combined with pH-responsive nanocarriers and tumor-specific ligands to improve targeting and drug release. Disulfide bonds can connect drugs, polymers, and carriers, facilitating targeted delivery and controlled release. Recent studies have explored various drug delivery systems based on disulfide bonds, including polymeric nanoparticles, liposomes, mesoporous silica nanoparticles, and others. These systems leverage the unique properties of disulfide bonds, such as their responsiveness to GSH and ROS, to enhance drug targeting and reduce systemic toxicity. Disulfide bonds also enable the design of multifunctional nanocarriers that can deliver multiple drugs, enhance therapeutic effects, and improve patient outcomes. The application of disulfide bonds in drug delivery systems has shown significant potential in improving cancer treatment by enhancing drug targeting, reducing side effects, and improving therapeutic efficacy. However, challenges remain in translating these systems into clinical practice, including optimizing drug loading, improving stability, and ensuring safe and effective delivery. Overall, disulfide bond-based drug delivery systems represent a promising strategy for targeted cancer therapy, with ongoing research aimed at further improving their clinical applicability.